PharmaCyte Biotech (OTCMKTS:PMCB) has started 2016 off with a bang. After delivering an impressive shareholder update, shares have surged off of last month's 52 week low. My previous article on PMCB was simply titled "Shareholders Of Pharmacyte Biotech Hope 2016 Is Better." Well judging from the look of things, it looks like I hit the nail on the head and 2016 is indeed going to be a heck of a lot better.The excitement and optimism over PMCB stems from its revolutionary technology Cell-in-a-Box. PMCB utilizes its signature live-cell encapsulation technology to develop treatments for cancer and diabetes. Its new treatment for pancreatic cancer is advancing into the clinic in the United States with study sites in Europe and Australia. CEO Kenneth Waggoner said in the update:
“We are excited to see 2016 arrive as this is the year that we will get into the clinic with our pancreatic cancer treatment. Our shareholders should understand that nothing whatsoever will deter our efforts to get into the clinic and to showcase our novel treatment for pancreatic cancer.”
Among the highlights that shareholders should look forward to this year include the Bangkok, Thailand manufacturing facility going into production. The facility is expected to receive a factory license from the Thai government any day now. This will allow the facility to produce the encapsulated cells for PharmaCyte to use in its clinical trial.PharmaCyte’s clinical trial in pancreatic cancer will get underway with Translational Drug Development (TD2) coordinating the trial globally and conducting it in the United States. Clinical Network Services (CNS) will conduct the trial in Europe and Australia in alliance with TD2. PMCB will also be talking to other cancer centers concerning patients that no longer benefit from receiving the “gold standard” treatment – the combination of gemcitabine and Abraxane. This is a critical unmet need and will boost the value of PMCB overnight.After the pancreatic cancer clinical trial has been in process for approximately six months, there will be an evaluation of PharmaCyte’s pancreatic cancer treatment on the patients enrolled in the trial with the interim results being reported. Additionally, preclinical studies will determine if PharmaCyte’s pancreatic cancer treatment can slow down the production and accumulation of malignant ascites fluid. If successful, plans to conduct a clinical trial in ascites will be undertaken by PharmaCyte with the goal of having TD2 begin the clinical trial by year end or early 2017.Regarding its diabetes treatments, numerous preclinical studies will be conducted concurrently and in parallel by members of PharmaCyte’s international Diabetes Consortium to condense the time it will take for PharmaCyte to enter into a clinical trial that will test the ability of the Melligen insulin-producing cells encapsulated using the Cell-in-a-Box® technology to treat Type 1 diabetes and insulin-dependent Type 2 diabetes, with the goal of reaching the clinic in 2017.Perhaps the biggest news for shareholders though is that PMCB will be attending the 2016 JP Morgan Healthcare conference in San Francisco to meet with pharmaceutical companies and potential institutional investors. Now reading between the lines, this is a pretty big deal as it's sponsored by JP Morgan. All the big pharma companies will be there as well as big hedge funds. It wouldn't surprise me that we see a deal get done and PMCB either forms a joint venture or is acquired. With a current market cap of around just $58 million, PMCB would be a drop in the bucket for a firm like Merck, Pfizer, or any of the other major drug companies that would love to gets its hands on PharmaCyte's technology.
To get the inside scoop on PMCB and to stay up to date on current developments
sign up below with your email
We Have A Monster Pick Coming Soon!
Don't Miss Out!
Sign Up Below!
PMCB is one of the most talked about names on the OTC markets. Shares have a history of volatility and are just starting their comeback after a disastrous 2015. PMCB is still in the developmental stages with no revenues and carries a great deal of risk. However, the company does have a seasoned management team lead by Kenneth Waggoner and has a great deal of potential if he and his team can deliver. Stay up to date on the exciting developments on PMCB and all of the other hot stocks that we cover. Sign up below!
Disclosure: We have no position in PMCB long or short and have not been compensated for this article.
Discover Hidden Gems
Don't miss the next big opportunity. Subscribe for timely alerts on potential market movers.
